In the last decade several therapeutic antibodies have been Federal Drug Administration
(FDA) and European Medicines Agency (EMEA) approved. Although their mechanisms of …

The cytokine Fms-like tyrosine kinase 3 ligand (FL) is an important regulator of
hematopoiesis. Its receptor, Flt3, is expressed on myeloid, lymphoid and dendritic cell …

Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal
hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute …

Antibody-based immunotherapy represents a promising strategy to target and eliminate
chemoresistant leukemic cells. Here, we evaluated the CD33/CD3-bispecific T cell engaging …

Background About half of AML patients achieving complete remission (CR) display
measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized …

Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce
remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic …

Acute myeloid leukemia (AML) is a highly heterogenous disease with multiple signaling
pathways contributing to its pathogenesis. A key driver of AML is the FMS-like tyrosine …

Simple Summary Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have
emerged as novel therapeutic modalities in the treatment of advanced hematological …

Background In lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-
T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success …